Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept

Carolyn I Rodriguez, Jordana Zwerling, Eyal Kalanthroff, Hanyang Shen, Maria Filippou, Booil Jo, Helen Blair Simpson, Ronald M Burch, Joseph R Moskal, Carolyn I Rodriguez, Jordana Zwerling, Eyal Kalanthroff, Hanyang Shen, Maria Filippou, Booil Jo, Helen Blair Simpson, Ronald M Burch, Joseph R Moskal

No abstract available

Keywords: AMPA; Clinical Drug Studies; GLYX-13; Ketamine; NMDA; OCD; Obsessive-Compulsive Disorder; Rapastinel.

Figures

Figure 1. Obsessive-compulsive, Depression, and Anxiety Severity Mean Scores at baseline, 90, and 230 minutes after a Single Infusion of Rapastinel (N=7)

At baseline, 90, and 230 minutes post infusion (rapastinel 10mg/kg), patients self-rated the severity of their obsessions and compulsions (YBOCCS [range 0–40]), anxiety (BAI [range 0–63]), and depression (BDI [range 0–63]). For the 90 and 230 minute assessments, patients were instructed to rate their symptoms over the past 60 minutes for all three measures. Means scores are plotted for each assessment measure. Abbreviation: YBOCCS = Yale-Brown Obsessive Compulsive Challenge Scale; BAI = Beck Anxiety Inventory; BDI = Beck Depression Inventory.